Is Bristol Myers Squibb's Dividend Actually Safe Right Now?
BMY's dividend looks tempting, but traders need to dig beneath the yield before buying in.
Bristol Myers Squibb has been flashing a fat dividend yield that income investors can't ignore. When yields run this high relative to peers, the market is usually telling you something — and it's not always good news. You need to ask whether that payout is built on solid ground or slowly cracking under pressure.
The core question is cash flow. Dividend safety lives and dies by how much free cash flow a company generates versus what it promises shareholders. BMY carries a significant debt load from past acquisitions, and its pipeline faces the classic Big Pharma patent cliff problem — blockbuster drugs losing exclusivity can gut revenue faster than most retail investors expect.
Read more US Forces Down Iranian Attack Drones in Direct Confrontation →
That said, BMY isn't a house of cards. The company still generates substantial revenue from its oncology and immunology franchises, and management has repeatedly signaled commitment to the dividend. Commitment is one thing; capacity is another. Watch the free cash flow coverage ratio closely — if that number shrinks quarter over quarter, the payout discussion gets a lot more uncomfortable.
For traders eyeing BMY as a yield play, the setup is binary. Either the pipeline delivers and the dividend holds firm, making the current price a genuine value entry. Or patent pressures compound faster than new drug approvals, and that yield gets cut — sending the stock down hard while income dries up simultaneously. That's a double hit you don't want.
Do your own stress-testing before chasing this yield. High-yield dividend stocks in the pharma space demand more scrutiny, not less. Continue reading at Yahoo Finance.
